CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty CLDF Committees 2023 GI Fellow Board of Advisors
Embassy of Education
Slide Library Publications Webcasts Abstract Library Committee Members
 
NASH Single Disease Content  
Publications
 
Slide Library
   Released: 2023
test
NASH PATHway to Treatment
Michael Charlton, MD
Rohit Loomba, MD
Maru E. Rinella, MD
97 slides
 
 
   Released: 2023
test
Advances in NAFLD/NASH
Kris V. Kowdley, MD
55 slides
 
 
   Released: 2022
test
 
   Released: 2022
test
 
   Released: 2022
test
Pearls and Pitfalls: Update on emerging therapies in NASH
Michael Charlton, MD & Rohit Loomba, MD
97 slides
 
 
   Released: 2021
test
The Puzzle in Hepatorenal Syndrome Management
Hugo E. Vargas, MD
40 slides
 
 
   Released: 2021
test
COVID-19 and Managing Liver Disease
K. Rajender Reddy, M.D.
33 slides
 
 
   Released: 2021
test
Alcohol-Associated Liver Disease
Michael R. Lucey MD
43 slides
 
 
   Released: 2021
test
Chronic Hepatitis B and D: Emerging Concepts and Treatment
Robert G Gish MD, FAASLD, AGAF, FAST
42 slides
 
 
   Released: 2021
test
Management of Refractory Hepatic Encephalopathy
Jasmohan S. Bajaj, MD
41 slides
 
 
   Released: 2021
test
Hepatitis C: Elimination Strategies in the US
David Bernstein, MD, FAASLD, FACG, FACP, AGAF
43 slides
 
 
   Released: 2021
test
Management of Hepatocellular Carcinoma in 2021
Laura Kulik, MD
45 slides
 
 
   Released: 2021
test
Hot Topics In Pediatric Liver Disease
Rohit Kohli, MBBS, MS
35 slides
 
 
   Released: 2021
test
Thrombocytopenia in CLD
Robert S. Brown, Jr., MD, MPH
32 slides
 
 
   Released: 2021
test
Cholestatic Liver Disease: Current Management and Emerging Therapies
Kris V. Kowdley MD
36 slides
 
 
   Released: 2021
test
Emerging Therapies in NASH
Stephen A Harrison, MD, FACP, FAASLD
32 slides
 
 
   Released: 2021
test
Identifying High Risk NASH Patients Using Noninvasive Techniques (NITs)
Mazen Noureddin, MD, MHSc
42 slides
 
 
   Released: 2021
test
Burden of NASH: Why Do We Need to Care?
21 slides
 
 
   Released: 2021
test
NASH Screening and Diagnosis in Primary Care and Endocrinology Practice Settings: The Role of NITs
52 slides
 
 
   Released: 2021
test
NASH Screening and Diagnosis in Specialty Clinics: The Role of Radiologic Modalities, Serum Fibrosis Tests and Algorithm
40 slides
 
 
   Released: 2021
test
Treatment Endpoints: Clinical vs Regulatory Endpoints
39 slides
 
 
   Released: 2021
test
Combination Therapies in NASH: What's Promising?
21 slides
 
 
   Released: 2021
test
Lifestyle Modification and Current Treatment Regimens for NAFLD
29 slides
 
 
   Released: 2021
test
New Targets for Emerging Therapies in NASH
26 slides
 
 
   Released: 2020
test
Imaging as an Outcome and Endpoint for Clinical Trials of NASH
29 slides
 
 
   Released: 2020
test
Clinical Management of NASH: Diet and Nutrition
41 slides
 
 
   Released: 2020
test
The Comprehensive Global Burden and Impact of NASH
32 slides
 
 
   Released: 2020
test
NAFLD and Cardiovascular Disease
43 slides
 
 
   Released: 2020
test
Imaging as an Outcome and Endpoint for Clinical Trials of NASH
29 slides
 
 
   Released: 2020
test
Challenges in Management and Clinical Trials of NASH in Children
26 slides
 
 
   Released: 2020
test
Weight Loss in NASH: Role of Weight Loss Medications and Surgery
17 slides
 
 
   Released: 2020
test
Why NASH and Exercise?
43 slides
 
 
   Released: 2020
test
Is Histologic Fibrosis Assessment an Appropriate Endpoint / Reference Standard for Clinical Trials?
25 slides
 
 
   Released: 2020
test
NASH and Diabetes Linkage: Where do we go from here?
42 slides
 
 
   Released: 2020
test
Serum Biomarkers and Clinical Algorithms in NASH: Utility in Clinical Trials and Clinical Practice
49 slides
 
 
   Released: 2020
test
Best Practices in NASH Management and Current Status of Drug Development
37 slides
 
 
   Released: 2020
test
Imaging as an Outcome and Endpoint for Clinical Trials of NASH
35 slides
 
 
   Released: 2020
test
NASH: Current Approach and When Will New Treatment Options Be Available?
39 slides
 
 
   Released: 2018
Webcast
NASH 2018
61 slides
 
 
   Released: 2016
Webcast
Get Ready for the Global Epidemic of NASH: Evolving Diagnosis and Treatment Strategies
66 slides
 
 
   Released: 2015
Webcast
Best of the Liver Summit: PBC, NAFLD/NASH and HCV
78 slides
 
 
   Released: 2015
Webcast
Hepatology Update: New Developments in PBC, NAFLD & NASH
77 slides
 
 
   Released: 2015
Webcast
THE LIVER SUMMIT
89 slides
 
 
 
 
Recorded Educational Webinar

 
 
 
Find a NASH Clinical Investigator
Audiocasts from the Symposia at UEGW 2016 - Vienna, Austria
Webcast Library
     
Advances in NAFLD/NASH - Kris V. Kowdley, MD   Educational Webcast
New Advances in NASH Diagnostics and Prognostics - Rohit Loomba, MD, MHSc   Educational Webcast
New Advances in NASH Diagnostics and Prognostics - Mazen Noureddin, MD, MHSc   Educational Webcast
Liver Connect 2022   Educational Webcast
NASH Connect 2022   Educational Webcast
Pearls and Pitfalls update on emerging therapies in NASH   Educational Webcast
2021 Liver Connect Conference   Educational Webcast
International NASH Summit   Educational Webcast
Building a Multi-Departmental Fatty Liver Management Program   Educational Webinar
NAFLD - NASH Treatment Outlook   Educational Webinar
Epidemiology and Pathophysiology of NAFLD - NASH   Educational Webinar
Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH   Educational Webinar
Implications of NAFLD in People with HIV   Educational Webinar
Implications of the NAFLD Epidemic on the Future of Liver Transplantation   Educational Webinar
Clinical Updates in the Management of Fatty Liver Disease in Patients with Type 2 Diabetes   Educational Webinar
Fatty Liver Disease in Adolescent and Pediatric Patients   Educational Webinar
Abstract Library
1.Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
 

Lancet Gastroenterol Hepatol. 2023 Aug;8(8):704-713.doi: 10.1016/S2468-1253(23)00141-3. Epub 2023 Jun 5.

Ferenc E Mózes 1, Jenny A Lee 2, Yasaman Vali 2, Osama Alzoubi 3, Katharina Staufer 4, Michael Trauner 5, Rafael Paternostro 5, Rudolf E Stauber 6, Adriaan G Holleboom 7, Anne-Marieke van Dijk 7, Anne Linde Mak 7, Jérôme Boursier 8, Marc de Saint Loup 9, Toshihide Shima 10, Elisabetta Bugianesi 11, Silvia Gaia 11, Angelo Armandi 11, Shalimar 12, Monica Lup?or-Platon 13, Vincent Wai-Sun Wong 14, Guanlin Li 14, Grace Lai-Hung Wong 14, Jeremy Cobbold 15, Thomas Karlas 16, Johannes Wiegand 16, Giada Sebastiani 17, Emmanuel Tsochatzis 18, Antonio Liguori 19, Masato Yoneda 20, Atsushi Nakajima 20, Hannes Hagström 21, Camilla Akbari 22, Masashi Hirooka 23, Wah-Kheong Chan 24, Sanjiv Mahadeva 24, Ruveena Rajaram 24, Ming-Hua Zheng 25, Jacob George 26, Mohammed Eslam 26, Salvatore Petta 27, Grazia Pennisi 27, Mauro Viganò 28, Sofia Ridolfo 29, Guruprasad Padur Aithal 30, Naaventhan Palaniyappan 30, Dae Ho Lee 31, Mattias Ekstedt 32, Patrik Nasr 32, Christophe Cassinotto 33, Victor de Lédinghen 34, Annalisa Berzigotti 35, Yuly P Mendoza 36, Mazen Noureddin 37, Emily Truong 38, Céline Fournier-Poizat 39, Andreas Geier 40, Miljen Martic 41, Theresa Tuthill 42, Quentin M Anstee 43, Stephen A Harrison 1, Patrick M Bossuyt 
 
2.Lifestyle interventions in nonalcoholic fatty liver disease
 

Nat Rev Gastroenterol Hepatol. 2023 Jul 4. doi: 10.1038/s41575-023-00800-4.Online ahead of print.

 

Zobair M Younossi 1 2 3, Shira Zelber-Sagi 4, Linda Henry 5 6, Lynn H Gerber 5 6
 
3.NAFLD-Related HCC: Focus on the Latest Relevant Preclinical Models
 

Cancers (Basel). 2023 Jul 22;15(14):3723. doi: 10.3390/cancers15143723.

 

Jing Fang 1 2, Séverine Celton-Morizur 1 2, Chantal Desdouets 1 2
 
4.Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
 

Ann N Y Acad Sci. 2023 Aug;1526(1):16-29. doi: 10.1111/nyas.15012.Epub 2023 Jul 3.

 

George Agyapong 1 2, Farzaneh Dashti 1, Bubu A Banini 1
 
5.Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study
 

Hepatology. 2023 May 11. doi: 10.1097/HEP.0000000000000439. Online ahead of print.

 

Quentin M Anstee 1, Kathryn J Lucas 2, Sven Francque 3 4 5, Manal F Abdelmalek 6, Arun J Sanyal 7, Vlad Ratziu 8, Adrian C Gadano 9, Mary Rinella 10, Michael Charlton 11, Rohit Loomba 12, Edward Mena 13, Jörn M Schattenberg 14, Mazen Noureddin 15, Donald Lazas 16, George Bb Goh 17, Shiv Kumar Sarin 18, Yusuf Yilmaz 19 20, Miljen Martic 21, Rowan Stringer 21, Jossy Kochuparampil 21, Li Chen 22, Gerardo Rodriguez-Araujo 23, Elaine Chng 24, Nikolai V Naoumov 21, Clifford Brass 22, Marcos C Pedrosa 21
 
6.Prospective study comparing hepatic steatosis assessment by magnetic resonance imaging and four ultrasound methods in 105 successive patients
 

World J Gastroenterol. 2023 Jun 14;29(22):3548-3560. doi: 10.3748/wjg.v29.i22.3548.

 

Remi Collin 1 2, Benoit Magnin 3, Constance Gaillard 3, Carine Nicolas 4, Armand Abergel 4, Benjamin Buchard 4
 
7.Evolution of pretransplant cardiac risk factor burden and major adverse cardiovascular events in liver transplant recipients over time
 

Liver Transpl. 2023 Jun 1;29(6):581-590. doi: 10.1097/LVT.0000000000000013.Epub 2023 Jan 3.

 

Claire R Harrington 1, Paul Levy 1, Elizabeth Cabrera 1, Jing Gao 1, Dyanna L Gregory 2, Cynthia Padilla 1, Gonzalo Crespo 3, Lisa B VanWagner 2
 
8.Gaps in Confirmatory Fibrosis Risk Assessment in Primary Care Patients with Nonalcoholic Fatty Liver Disease
 

Dig Dis Sci. 2023 Jul;68(7):2946-2953. doi: 10.1007/s10620-023-07959-5. Epub 2023 May 16.

 

Joseph A Moore 1, William H Wheless 1, Jingwen Zhang 1, Justin Marsden 1, Patrick D Mauldin 1, William P Moran 1, Andrew D Schreiner 2
 
9.Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL)
 

Mol Metab. 2023 Jul;73:101728. doi: 10.1016/j.molmet.2023.101728. Epub 2023 Apr 19.

 

Gabriele Mocciaro 1, Michael Allison 2, Benjamin Jenkins 3, Vian Azzu 4, Isabel Huang-Doran 2, Luis Vicente Herrera-Marcos 5, Zoe Hall 6, Antonio Murgia 7, Davies Susan 2, Mattia Frontini 8, Antonio Vidal-Puig 3, Albert Koulman 9, Julian L Griffin 10, Michele Vacca 11
 
10.The Association between Liver Enzymes and Mortality Stratified by Non-Alcoholic Fatty Liver Disease: An Analysis of NHANES III
 

Nutrients. 2023 Jul 7;15(13):3063. doi: 10.3390/nu15133063.

 

Saskia Rita Grob 1, Flurina Suter 2, Verena Katzke 3, Sabine Rohrmann 2
 
11.You Are What You Eat: A Review on Dietary Interventions for Treating Pediatric Nonalcoholic Fatty Liver Disease
 

Nutrients. 2023 Jul 28;15(15):3350. doi: 10.3390/nu15153350.

 

Piper Sandel 1, Lawrence Ma 1, Helen Wang 1, Eric A Pasman 2 3
 
12.Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age
 

Hepatol Commun. 2023 Jun 2;7(6):e0148. doi: 10.1097/HC9.0000000000000148.eCollection 2023 Jun 1.

 

Matthew J Miller 1, Emily Harding-Theobald 2, Jacob V DiBattista 1, Zhe Zhao 2, Karn Wijarnpreecha 2, Anna S Lok 2, Vincent L Chen 2
 
13.High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold
 

Diabetes Care. 2023 Jul 1;46(7):1354-1362. doi: 10.2337/dc22-2048.

 

Laurent Castera 1 2, Cédric Laouenan 3 4, Anaïs Vallet-Pichard 5, Tiphaine Vidal-Trécan 6, Pauline Manchon 4, Valérie Paradis 1 7, Dominique Roulot 8 9, Nathalie Gault 4, Christian Boitard 10 11, Benoit Terris 10 12, Hélène Bihan 13 14, Jean-Baptiste Julla 6 15, Alina Radu 16, Thierry Poynard 17 18 19, Angélique Brzustowsky 20, Etienne Larger 10 11, Sébastien Czernichow 16 21, Stanislas Pol 5 10, Pierre Bedossa 1 22, Dominique Valla 1 2, Jean-François Gautier 6 15; QUID-NASH investigators

Collaborators

  • QUID-NASH investigators: 

Christophe Junot, Bernard Van Beers, Christian Boitard, Nathalie de Préville, Isabelle Durand Zaleski, Pierre-Emmanuel Rautou, Marco Dioguardi, Valérie Vilgrain, Jean-Pierre Riveline
 
14.Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis
 

Gut. 2023 Jul;72(7):1399-1409. doi: 10.1136/gutjnl-2022-328689.Epub 2023 Jan 4.

 

Federico Ravaioli # 1 2 3, Elton Dajti # 2 3, Alessandro Mantovani 4, Philip Noel Newsome 5 6, Giovanni Targher 4, Antonio Colecchia 7
 
15.Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness
 

Dig Dis Sci. 2023 Jun;68(6):2695-2703. doi: 10.1007/s10620-022-07809-w. Epub 2023 Jan 24.

 

Jessica Dahmus 1, Breianna Hummer 1, Gloriany Rivas 1, Kathryn Schmitz 2 3 4 5, Stephen H Caldwell 6, Curtis K Argo 6, Ian Schreibman 1 7, Jonathan G Stine 8 9 10 11
 
16.Accuracy of ultrasonographic fatty liver index using point-of-care ultrasound in stratifying non-alcoholic fatty liver disease patients
 

Eur J Gastroenterol Hepatol. 2023 Jun 1;35(6):654-661. doi: 10.1097/MEG.0000000000002544.Epub 2023 Apr 15.

 

Achuthan Sourianarayanane 1, Arthur J McCullough 2
 
17.Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes
 

Hepatology. 2023 Jul 1;78(1):195-211. doi: 10.1097/HEP.0000000000000351.Epub 2023 Mar 17.

 

Grazia Pennisi 1, Marco Enea 1, Vincenzo Falco 2, Guruprasad P Aithal 3 4, Naaventhan Palaniyappan 3 4, Yusuf Yilmaz 5, Jerome Boursier 6 7, Christophe Cassinotto 8, Victor de Lédinghen 9, Wah Kheong Chan 10, Sanjiv Mahadeva 10, Peter Eddowes 3 4, Philip Newsome 3 4, Thomas Karlas 11, Johannes Wiegand 11, Vincent Wai-Sun Wong 12, Jörn M Schattenberg 13 14, Christian Labenz 13 14, Won Kim 15, Myoung Seok Lee 15, Monica Lupsor-Platon 16, Jeremy F L Cobbold 17, Jian-Gao Fan 18, Feng Shen 18, Katharina Staufer 19 20, Michael Trauner 19, Rudolf Stauber 21, Atsushi Nakajima 22, Masato Yoneda 22, Elisabetta Bugianesi 23, Ramy Younes 23, Silvia Gaia 23, Ming-Hua Zheng 24 25, Calogero Cammà 1 2, Quentin M Anstee 26 27, Ferenc E Mózes 28, Michael Pavlides 17 28, Salvatore Petta 1 2
 
18.US Quantification of Liver Fat: Past, Present, and Future
 

Radiographics. 2023 Jul;43(7):e220178. doi: 10.1148/rg.220178.

 

David T Fetzer 1, Theodore T Pierce 1, Michelle L Robbin 1, Guy Cloutier 1, Arjmand Mufti 1, Timothy J Hall 1, Anil Chauhan 1, Reinhard Kubale 1, An Tang 1
 
19.The prevalence and risk factors for cognitive impairment in obesity and NAFLD
 

Hepatol Commun. 2023 Jun 28;7(7):e00203. doi: 10.1097/HC9.0000000000000203.eCollection 2023 Jul 1.

 

Charlotte W Wernberg 1 2, Lea L Grønkjær 1, Birgitte Gade Jacobsen 1, Vineesh Indira Chandran 3, Aleksander Krag 2, Jonas H Graversen 3, Karin Weissenborn 4, Hendrik Vilstrup 5, Mette M Lauridsen 1
 
20.Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
 

Hepatol Int. 2023 Jun;17(3):584-594. doi: 10.1007/s12072-022-10469-7. Epub 2023 Feb 3.

 

Phillip E Melton 1 2, M A Burton 3, K A Lillycrop 4 5, K M Godfrey 5 6, S Rauschert 7, D Anderson 7, G C Burdge 8, T A Mori 9, L J Beilin 9, O T Ayonrinde 9 10, J M Craig 11 12, J K Olynyk 10 13, J D Holbrook 6, C E Pennell 14, W H Oddy 15, E K Moses 15 16, L A Adams 9, R C Huang 7
 
21.Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study
 

BMJ Open. 2023 Jul 3;13(7):e070431.doi: 10.1136/bmjopen-2022-070431.

 

Willy B Theel 1 2 3, Bianca M Boxma-de Klerk 4 5, Femme Dirksmeier-Harinck 6, Elisabeth Fc van Rossum 2 3, Danny A Kanhai 7, Jan A Apers 8, Bas M van Dalen 9, Robert J De Knegt 10, Bojou Neecke 11, Ellen M van der Zwan 12, Diederick E Grobbee 13, Thomas Hankemeier 14, Janneke Wiebolt 2, Manuel Castro Cabezas 3 15
 
22.A multi-society Delphi consensus statement on new fatty liver disease nomenclature
 

J Hepatol. 2023 Jun 20;S0168-8278(23)00418-X. doi: 10.1016/j.jhep.2023.06.003.Online ahead of print.

 

Mary E Rinella 1, Jeffrey V Lazarus 2, Vlad Ratziu 3, Sven M Francque 4, Arun J Sanyal 5, Fasiha Kanwal 6, Diana Romero 7, Manal F Abdelmalek 8, Quentin M Anstee 9, Juan Pablo Arab 10, Marco Arrese 11, Ramon Bataller 12, Ulrich Beuers 13, Jerome Boursier 14, Elisabetta Bugianesi 15, Christopher Byrne 16, Graciela E Castro Narro 17, Abhijit Chowdhury 18, Helena Cortez-Pinto 19, Donna Cryer 20, Kenneth Cusi 21, Mohamed El-Kassas 22, Samuel Klein 23, Wayne Eskridge 24, Jiangao Fan 25, Samer Gawrieh 26, Cynthia D Guy 27, Stephen A Harrison 28, Seung Up Kim 29, Bart Koot 30, Marko Korenjak 31, Kris Kowdley 32, Florence Lacaille 33, Rohit Loomba 34, Robert Mitchell-Thain 35, Timothy R Morgan 36, Elisabeth Powell 37, Michael Roden 38, Manuel Romero-Gómez 39, Marcelo Silva 40, Shivaram Prasad Singh 41, Silvia C Sookoian 42, C Wendy Spearman 43, Dina Tiniakos 44, Luca Valenti 45, Miriam B Vos 46, Vincent Wai-Sun Wong 47, Stavra Xanthakos 48, Yusuf Yilmaz 49, Zobair Younossi 50, Ansley Hobbs 7, Marcela Villota-Rivas 51, Philip N Newsome 52; NAFLD Nomenclature consensus group

Collaborators

NAFLD Nomenclature consensus group: 

Veeral Ajmeral, William Alazawi, Maryam Alkhatry, Naim Alkhouri, Alina Allen, Michael Allison, Khalid Alswat, Mario R Alvares-da-Silva, Michele Alves-Bezerra, Matthew J Armstrong, Diego Arufe, Pablo Aschner, Gyorgy Baffy, Meena Bansal, Pierre Bedossa, Renata Belfort, Thomas Berg, Annalisa Berzigotti, Michael Betel, Cristiana Bianco, Clifford Brass, Carol L Brosgart<
 
23.Magnetic resonance Elastography-Based prediction model for hepatic decompensation in NAFLD; a Multi-Center cohort study
 

Hepatology. 2023 May 22. doi: 10.1097/HEP.0000000000000470. Online ahead of print.

 

Beom Kyung Kim 1 2, Jaclyn Bergstrom 1, Rohan Loomba 1, Nobuharu Tamaki 1 3, Namiki Izumi 3, Atsushi Nakajima 4, Ramazan Idilman 5, Mesut Gumussoy 5, Digdem Kuru Oz 6, Ayse Erden 6, Emily Truong 7, Ju Dong Yang 7, Mazen Noureddin 7, Alina M Allen 8, Rohit Loomba 1 9, Veeral Ajmera 1
 
24.The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women
 

Nutrients. 2023 Jun 8;15(12):2670. doi: 10.3390/nu15122670.

 

Johanna K DiStefano 1
 
25.Identification of High Risk NAFLD Patients in Endocrinology Clinics
 

Endocr Pract. 2023 Jul 3;S1530-891X(23)00469-X.doi: 10.1016/j.eprac.2023.06.012. Online ahead of print.

Zobair M Younossi 1, Linda Henry 2, Scott Isaacs 3, Kenneth Cusi 
 
View More
 
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

NASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2023 GI Fellow Board of Advisors

Other Resources

Journal Abstracts
Hep C Link to Care

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2023 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.